Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Annual Review – Plain English Edition

Let’s cut through the jargon and see how Anebulo did this year. Imagine we’re chatting at your kitchen table – no fluff, just the facts that matter for investors.

---

1. The Big Picture: What They Do & How 2023 Went
Anebulo’s working on a pill to reverse scary cannabis overdoses (think edibles gone wrong) and other substance issues. Their drug aims to block the “high” and prevent ER visits.
This year’s progress:

• Early trial results looked promising (beats placebo!).
• Still years away from FDA approval – no product to sell yet.

---

2. Money Checkup: Are They Burning Cash?

• Revenue: Still $0 (normal for biotech startups in R&D mode).
• Spending: Burned $12M this year (up from $8M last year) on trials and research.
• Runway: ~$20M cash left. At this rate, they’ve got about 2 years before needing more funding.
  Takeaway: No surprises here. Growth = clinical progress, not sales (yet).

---

3. Highlights & Stumbles
✅ Wins:

• Landed FDA “Fast Track” status (could speed up reviews).
• Teamed up with a major pharma company for drug manufacturing.
• Early trial data showed their pill actually works.

🚩 Stumbles:

• A key trial got delayed (supply chain hiccups).
• Stock dropped 30% as investors got antsy waiting for updates.

---

4. Financial Health: Stable or Shaky?

• No debt – big plus!
• Cash cushion: 2 years left if spending stays steady.
• Big risk: If trials fail, they’ll need to raise more money (likely by selling shares, which could hurt stock value).

---

5. What Keeps the CEO Up at Night?

• Trial failure: Later-stage results could flop (stock would tank).
• FDA delays: More waiting = more cash burned.
• Competition: A rival biotech is testing a similar drug (but theirs requires an IV drip – Anebulo’s pill is easier).

---

6. Strategic Moves: New Players & Focus

• Hired a new Chief Medical Officer with deep FDA experience (smart play for trial navigation).
• Dropped side projects to go all-in on the cannabis overdose drug (no distractions).

---

7. What’s Coming in 2024?

• Phase 2b trials (mid-stage testing) starting soon. Results expected late 2024.
• Make-or-break moments: Partnership deals, FDA updates, or surprise positive data could move the stock.
• Watch for: Possible stock offerings to raise cash (common in biotech, but dilutes shares).

---

8. Market Trends: Tailwinds or Headwinds?

• Opportunity: More states legalizing cannabis → rising ER visits for overdoses → bigger market for their drug.
• Risk: FDA tightening rules for addiction treatments (could slow approvals).

---

Bottom Line for Investors
High risk, high potential reward.

• 👍 Why you might like it:
  • Solves a growing problem (cannabis ER visits up 45% in legal states).
  • No debt + promising early data = credible underdog story.
• 👎 Why you might pass:
  • Years from profitability, with a high chance of trial setbacks.
  • Competitors have deeper pockets and may sprint ahead.

Best for: Investors who can stomach volatility and have a long timeline. If their drug works, this could 10x. If not, it might go to zero. Watch trial updates like a hawk!

---

P.S. – Anebulo’s annual report skipped some details investors might expect. Always dig deeper before deciding! 😊